IN8BIO, INC. cotiza a 1.18 USD y tiene una capitalización bursátil de $12M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed gl…
| Periodo | 2026-08 | 2026-05 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | $-0.25 | $-0.26 | $-0.45 | $-0.85 |
| Estimado | $-0.37 | $-0.69 | $-0.47 | $-1.25 |
| Sorpresa | +32.4% | +62.3% | +4.3% | +32.0% |
| Métrica | INAB | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -70.5% | -40.4% | -30.1% |
| ROA | -60.2% | -32.0% | -28.2% |
| Current Ratio | 8.82 | 2.84 | +5.98 |
| Debt / Equity | — | 0.28 | — |